Retsky Michael, Bonadonna Gianni, Demicheli Romano, Folkman Judah, Hrushesky William, Valagussa Pinuccia
Department of Surgical Research, Children's Hospital and Harvard Medical School, Boston, MA, USA.
Breast Cancer Res. 2004;6(4):R372-4. doi: 10.1186/bcr804. Epub 2004 May 14.
We suggest that surgical extirpation of primary breast cancer among other effects accelerates relapse for some premenopausal node-positive patients. These accelerated relapses occur within 10 months of surgery for untreated patients. The mechanism proposed is a stimulation of angiogenesis for distant dormant micrometastases. This has been suggested as one of the mechanisms to explain the mammography paradox for women aged 40-49 years. We could imagine that it also plays a role in adjuvant chemotherapy effectiveness since, perhaps not coincidentally, this is most beneficial for premenopausal node-positive patients.
We speculate that there is a burst of angiogenesis of distant dormant micrometastases after surgery in approximately 20% of premenopausal node-positive patients. We also speculate that this synchronizes them into a temporal highly chemosensitive state and is the underlying reason why adjuvant chemotherapy works particularly well for that patient category. Furthermore, this may explain why cancer in younger patients is more often 'aggressive'.
Stimulation of dormant micrometastases by primary tumor removal is known to occur in animal models. However, we need to determine whether it happens in breast cancer. Transient circulating levels of angioactive molecules and serial high-resolution imaging studies of focal angiogenesis might help.
Short-course cytotoxic chemotherapy after surgery has probably reached its zenith, and other strategies, perhaps antiangiogenic methods, are needed to successfully treat more patients. In addition, the hypothesis predicts that early detection, which is designed to find more patients without involved lymph nodes, may not be a synergistic strategy with adjuvant chemotherapy, which works best with positive lymph node patients.
我们认为,对于一些绝经前淋巴结阳性的患者,原发性乳腺癌的手术切除在产生其他影响的同时,会加速复发。这些加速复发发生在未接受治疗的患者术后10个月内。提出的机制是对远处休眠微转移灶的血管生成有刺激作用。这被认为是解释40 - 49岁女性乳房X线摄影悖论的机制之一。我们可以想象,它在辅助化疗效果中也起作用,因为这对绝经前淋巴结阳性患者最有益,这或许并非巧合。
我们推测,大约20%的绝经前淋巴结阳性患者术后会出现远处休眠微转移灶的血管生成爆发。我们还推测,这会使它们同步进入一个对化疗高度敏感的暂时状态,这是辅助化疗对该类患者效果特别好的根本原因。此外,这可能解释了为什么年轻患者的癌症更常具有“侵袭性”。
已知在动物模型中,原发性肿瘤切除会刺激休眠微转移灶。然而,我们需要确定这在乳腺癌中是否会发生。血管活性分子的短暂循环水平以及局灶性血管生成的系列高分辨率成像研究可能会有所帮助。
术后短程细胞毒性化疗可能已达到顶峰,需要其他策略,或许是抗血管生成方法,来成功治疗更多患者。此外,该假设预测,旨在发现更多无淋巴结受累患者的早期检测,可能不是与辅助化疗的协同策略,辅助化疗对淋巴结阳性患者效果最佳。